Audited financial statements of Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) Pharmaceutical (Shanghai) Co., Ltd. for 2021
Beijing Institute of Certified Public Accountants
Business report unified coding reporting system
Unified business reporting code: 110 Andon Health Co.Ltd(002432) 022761004068
Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) Pharmaceutical (Shanghai) Co., Ltd. annual report name:
audit
Report No.: Ernst & Young Huaming (2022) SZ No. 60468439b01
Name of audited (inspected) unit: Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) Pharmaceutical (Shanghai) Co., Ltd
Name of accounting firm: Ernst & Young Huaming Certified Public Accountants (special general partnership)
Business type: financial statement audit
Report opinion type: unqualified opinion
Report date: March 28, 2022
Filing date: March 28, 2022
Bao Xiaogang (110 Andon Health Co.Ltd(002432) 550),
Signed by:
Xia Chanyu (31 Shenzhen Zhenye(Group)Co.Ltd(000006) 619)
(information can be queried by scanning QR code or logging into the official website of Beijing injection Association)
Note: this filing information only proves that the report has been filed with the Beijing Institute of certified public accountants, and does not mean that the Beijing Institute of Certified Public Accountants makes any form of guarantee for the content of the report in any sense.
catalogue
Page audit report 1 – 7 audited financial statements
Consolidated balance sheet 8 – 9 consolidated income statement 10 – 11 consolidated statement of changes in shareholders’ equity 12
Consolidated cash flow statement 13 – 14 company balance sheet 15 – 16 company income statement 17
Statement of changes in shareholders’ equity 18
Cash flow statement of the company 19 – 20 notes to financial statements 21 – 119 supplementary information
1. Detailed statement of non recurring gains and losses 1
2. Return on net assets and earnings per share 2
1、 Basic information Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) Pharmaceutical (Shanghai) Co., Ltd. (“the company”) was jointly initiated and established by China CITIC Co., Ltd. (formerly known as “CITIC Pacific Co., Ltd.” (“CITIC”) and Shanghai Xingsheng Pharmaceutical Co., Ltd. (formerly known as “Shanghai Lansheng Guojian Pharmaceutical Co., Ltd.” (“Xingsheng pharmaceutical”) on January 25, 2002. According to the resolution of the founding meeting and the first general meeting of shareholders held on March 21, 2010, on March 11, 2010, the company converted into a joint stock limited company with the audited net assets of 66579930860 yuan on December 31, 2009 at the ratio of 1:0.676, of which 45000000000 yuan was converted into the share capital of the company, and the balance of 21579930860 yuan was used as the capital reserve of the company, It has been verified by Ernst & Young Huaming certified public accountants. Approved by the stock listing committee of the science and Innovation Board of Shanghai Stock Exchange on May 11, 2020, and approved by the reply on Approving the registration of initial public offering of Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) Pharmaceutical (Shanghai) Co., Ltd. (zjxk [2020] No. 1217) of China Securities Regulatory Commission on June 23, 2020, On July 22, 2020, the company made an initial public offering of 61621142 RMB ordinary shares (A shares) on the science and Innovation Board of Shanghai Stock Exchange at an issue price of 28.18 yuan per share. The company’s unified social credit code is 91310 Luoniushan Co.Ltd(000735) 408592g, and its registered address is No. 399, libing Road, China (Shanghai) pilot free trade zone. The company and its subsidiaries (hereinafter referred to as “the group”) belong to the biotechnology pharmaceutical industry. The business scope of the company is: research and development of biological products, genetic engineering products, Chinese and Western medicine and biological reagents (except the timely development and application of human stem cells, gene diagnosis and treatment); Production and sales of bioengineering products and self-produced products; Technology transfer, technical services and technical consultation of R & D achievements of relevant projects (for projects that must be approved according to law, business activities can be carried out only after being approved by relevant departments). The financial statements were approved by the board of directors of the company on March 28, 2022. The consolidation scope of the consolidated financial statements is determined on the basis of control. See note VI for the changes in this year. 2、 Preparation basis of financial statements the financial statements are prepared in accordance with the accounting standards for business enterprises – Basic Standards issued by the Ministry of Finance and the specific accounting standards, application guidelines, interpretations and other relevant provisions issued and revised later (collectively referred to as “accounting standards for business enterprises”).
The financial statements are presented on a going concern basis. When preparing the financial statements, except for some financial instruments, the valuation principle is historical cost. If an asset is impaired, the corresponding impairment provision shall be withdrawn in accordance with relevant regulations.
Notes to financial statements (Continued) III. important accounting policies and accounting estimates the group has formulated specific accounting policies and accounting estimates according to the actual production and operation characteristics, which are mainly reflected in the provision for bad debts of accounts receivable, inventory valuation method, depreciation of fixed assets, amortization of intangible assets, capitalization conditions of R & D expenses, revenue recognition and measurement, etc. 1. In accordance with the statement of accounting standards for business enterprises, the financial statements comply with the requirements of accounting standards for business enterprises and truly and completely reflect the financial position of the company and the group as of December 31, 2021 and the operating results and cash flow of 2021. 2. The accounting period of the group is the Gregorian calendar year, i.e. from January 1 to December 31. 3. Bookkeeping base currency the bookkeeping base currency of the group and the currency used in the preparation of the financial statements are RMB. Unless otherwise specified, it is expressed in RMB. Subsidiaries and associated enterprises of the group determine their recording currency according to the main economic environment in which they operate, and convert it into RMB when preparing financial statements. 4. Business combination business combination is divided into business combination under the same control and business combination not under the same control. Business combination under the same control: a business combination under the same control refers to a business combination in which the enterprises participating in the combination are ultimately controlled by the same party or the same parties before and after the combination, and the control is not temporary. For business combinations under the same control, the party that obtains control over other enterprises participating in the merger on the merger date is the merging party, and other enterprises participating in the merger are the merged party. The merger date refers to the date on which the combining party actually obtains control over the merged party. The assets and liabilities acquired by the combining party in the business combination under the same control (including the goodwill formed by the final controller’s acquisition of the combined party) shall be subject to relevant accounting treatment based on the book value in the final controller’s financial statements on the combination date. For the difference between the book value of the net assets obtained by the combining party and the book value of the merger consideration paid (or the total face value of the issued shares), the equity premium in the capital reserve shall be adjusted. If it is insufficient to offset, the retained earnings shall be adjusted.
Notes to financial statements (Continued) III. important accounting policies and accounting estimates (Continued) 4 Business combination (Continued) business combination not under the same control. If the enterprise participating in the combination is not ultimately controlled by the same party or the same parties before and after the combination, it is a business combination not under the same control. For business combinations not under the same control, the party that obtains control over other enterprises participating in the merger on the acquisition date is the acquirer, and other enterprises participating in the merger are the acquiree. The date of purchase refers to the date on which the purchaser actually obtains control over the acquiree. The identifiable assets, liabilities and contingent liabilities of the acquiree obtained in the business combination not under the same control shall be measured at fair value on the acquisition date. The difference between the sum of the fair value of the merger consideration paid (or the fair value of the equity securities issued) and the fair value of the equity of the acquiree held before the acquisition date is greater than the fair value share of the identifiable net assets of the acquiree obtained in the merger is recognized as goodwill and subsequently measured at cost less accumulated impairment losses. If the sum of the fair value of the merger consideration paid (or the fair value of the equity securities issued) and the fair value of the equity of the acquiree held before the acquisition date is less than the fair value share of the identifiable net assets of the acquiree obtained in the merger, the identifiable assets The measurement of the fair value of liabilities and contingent liabilities, the fair value of the merger consideration paid (or the fair value of equity securities issued) and the fair value of the equity held by the acquiree before the acquisition date shall be reviewed, If the sum of the fair value of the merger consideration paid after review (or the fair value of the equity securities issued) and the fair value of the equity of the acquiree held before the acquisition date is still less than the fair value share of the identifiable net assets of the acquiree obtained in the merger, the difference shall be included in the current profits and losses. If the business combination not under the same control is realized step by step through multiple transactions, the long-term equity investment held by the acquiree before the acquisition date shall be re measured according to the fair value of the long-term equity investment on the acquisition date, and the difference between the fair value and its book value shall be included in the current profit and loss; The other comprehensive income of the long-term equity investment of the acquiree held before the acquisition date under the equity method shall be accounted for on the same basis as the direct disposal of relevant assets or liabilities by the investee. Other changes in shareholders’ equity other than net profit and loss, other comprehensive income and profit distribution shall be transferred to the current profit and loss on the acquisition date. For the equity instrument investment held by the acquiree before the acquisition date, the changes in the fair value of the equity instrument investment accumulated in other comprehensive income before the acquisition date are transferred to retained profits and losses. 5. Consolidated financial statements the consolidation scope of consolidated financial statements is determined on the basis of control, including the financial statements of the company and all subsidiaries. Subsidiaries refer to the entities controlled by the company (including the separable parts of enterprises and invested units, as well as the structured entities controlled by the company). When preparing the consolidated financial statements, the accounting policies of subsidiaries that may be inconsistent with the company have been adjusted in accordance with the accounting policies of the company. Assets, liabilities, equity, income, expenses and cash flows arising from all transactions between companies within the group are fully offset at the time of consolidation.
Notes to financial statements (Continued) III. important accounting policies and accounting estimates (Continued) 5 Consolidated financial statements (Continued): if the current loss shared by minority shareholders of a subsidiary exceeds the share of minority shareholders in the opening shareholders’ equity of the subsidiary, the balance shall still be offset against the reduced shareholders’ equity. For subsidiaries acquired through business combination not under the same control, the operating results and cash flow of the acquiree shall be included in the consolidated financial statements from the date when the group obtains control until the group terminates its control. When preparing the consolidated financial statements, the financial statements of subsidiaries shall be adjusted on the basis of the fair value of all identifiable assets, liabilities and contingent liabilities determined on the acquisition date. For subsidiaries obtained through business combination under the same control, the operating results and cash flow of the combined party shall be included in the consolidated financial statements from the beginning of the current period. When preparing and comparing the consolidated financial statements, the relevant items of the previous financial statements are adjusted, which is regarded as the reporting entity formed after the merger has existed since the final controller began to implement control. If changes in relevant facts and circumstances lead to changes in one or more of the control elements, the group reassesses whether to control the investee. Under the condition of not losing control, the change of minority shareholders’ equity is regarded as equity transaction. If the equity investment in a subsidiary is disposed step by step through multiple transactions until the control right is lost, which belongs to a package deal, each transaction shall be treated as a transaction to dispose of a subsidiary and lose the control right; However, before the loss of control, the difference between each disposal price and the share of the subsidiary’s net assets corresponding to the disposal of investment shall be recognized as other comprehensive income in the consolidated financial statements, and shall be transferred to the profit and loss of the current period when the control is lost. If the equity investment in a subsidiary is disposed step by step through multiple transactions until the control right is lost, which is not a package deal, the corresponding accounting treatment shall be carried out for each transaction according to whether the control right is lost. If the control right is not lost, the change of minority shareholders’ equity shall be treated as an equity transaction. In case of loss of control, the remaining equity shall be re measured according to its fair value on the date of loss of control; The difference between the sum of the consideration obtained from the disposal of equity and the fair value of the remaining equity minus the share of the net assets of the original subsidiary continuously calculated from the purchase date calculated according to the original shareholding ratio shall be included in the current profits and losses of the loss of control; If there is goodwill to the subsidiary, the amount of goodwill shall be deducted when calculating and determining the profit and loss of disposal of the subsidiary; Other comprehensive income related to the equity investment of the original subsidiary is directly disposed of with the subsidiary when the control right is lost
